Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Bereik: RWE retrospectief onderzoek om de impact van cenobamaat op het gebruik van gezondheidszorg te evalueren

10 november 2026 bijgewerkt door: Aziende Chimiche Riunite Angelini Francesco S.p.A

Retrospectieve evaluatie van het gebruik van Cenobamate's gebruik van gezondheidszorg (HCRU) bij het beheer van ongecontroleerde focale aanval van het begin- een retrospectieve, kaartbeoordelingsstudie

The Study is an observational, retrospective study which aim is to assess cenobamate's healthcare resources utilization (HCRU) in the management of uncontrolled focal onset seizures. The amin objective is to compare the resource utilization before and after the use of cenobamate. Data from medical charts will be used and inserted into the eCRF from which the analyses will be conducted. Data from 200 patients from 10 sites in 5 countries are included.

Studie Overzicht

Studietype

Observationeel

Inschrijving (Werkelijk)

117

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Germany
      • Freiburg im Breisgau, Germany, Duitsland
        • Epilepsiezentrums am Neurozentrum des Universitätsklinikum Freiburg
      • Hamburg, Germany, Duitsland
        • Epileptologicum
      • Kork, Germany, Duitsland
        • Diakonie Kork, Epilepsiezentrum
    • Netherlands
      • Heeze, Netherlands, Nederland
        • Kempenhaeghe - Academisch Centrum voor Epilepsie
    • Spain
      • Barcelona, Spain, Spanje
        • Epilepsy Unit - Neurology Department Valle de Hebron Hospital
      • Madrid, Spain, Spanje
        • Epilepsy Unit of the Neurology Department of the Hospital Clínico San Carlos
      • Valencia, Spain, Spanje
        • Consorcio Hosp. General Universitario Valencia
    • UK
      • Glasgow, UK, Verenigd Koninkrijk
        • Institute of Neurosciences NHS Greater Glasgow and Clyde
      • Wolverhampton, UK, Verenigd Koninkrijk
        • Epilepsies - The Royal Wolverhampton NHS Trust
    • Switzerland
      • Zurich, Switzerland, Zwitserland
        • Department of Neurology, University Hospital Zurich

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more anti-seizure medications (ASMs), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and healthcare resources utilization (HCRU) (if any) prior to cenobamate starting date.

Beschrijving

Inclusion Criteria:

  1. Male and female patients of any ethnic origin ≥18 years old at index date;
  2. Patients with a diagnosis of epilepsy with uncontrolled focal-onset seizures despite the previous treatment with from 2 to 5 ASMs who started treatment with cenobamate at index date;
  3. Patients presenting at least 1 seizure a month in the last 6 months prior to index date;
  4. Patients with at least 6 months of data coverage in the medical records prior to the index date;
  5. Patients with at least 12 months of data in the medical records after index date (with a maximum interval between data of 6 months).
  6. Patients who give the consent to the processing of personal data according to the General Data Protection Regulation (GDPR) and/or other applicable local regulation.

Exclusion Criteria:

  1. Patients who meet any of the contraindications to the administration of adjunctive ASMs according to their approved SmPC;
  2. Patients who started cenobamate within an EAP;
  3. Progressive neurological disease, including degenerative CNS diseases and/or progressive brain tumors;
  4. Patients with specific syndrome (e.g. LGS and Dravet);
  5. Pregnancy or lactation;
  6. Patients without self-judgement ability;
  7. Patients with substance and alcohol abuse or dependence (except for caffeine and nicotine);
  8. Patients participating in any pharmacological or nonpharmacological interventional study starting from 6 months before the index date.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: RETROSPECTIVE

Cohorten en interventies

Groep / Cohort
Adult patients affected by epilepsy with focal-onset seizures

Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more ASMs (anti-seizure medications), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and HCRU (if any) prior to cenobamate starting date.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Tijdsspanne: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU, will be collected the number of epilepsy/epilepsy treatment-related hospitalizations during all the observation period

0-12 months
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Tijdsspanne: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU,will be collected the length of epilepsy/epilepsy treatment-related hospitalizations during all the observation period

0-12 months
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Tijdsspanne: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related outpatient visits (OP) during all the observation period

0-12 months
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Tijdsspanne: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related emergency room (ER) visits;

0-12 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tijdsspanne: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Switch/add-on of other ASMs

0-12 months
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tijdsspanne: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the dose of co-ASMs

0-12 months
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tijdsspanne: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the number of co-ASMs

0-12 months
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tijdsspanne: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Time to discontinuation of ASMs

0-12 months
Impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care
Tijdsspanne: 0-12 months

To evaluate the impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care, the number of epilepsy/epilepsy treatment related emergency care, ambulance use, the number of outpatient visits with neurologists, and the number of epilepsy specialist nurses' intervention will be collected;

0-12 months
Effectiveness of cenobamate used as adjunctive therapy
Tijdsspanne: 0-12 months

To evaluate the effectiveness of cenobamate used as adjunctive therapy, seizure frequency at baseline and at routinely scheduled follow-up visits, till the end of observation will be collected. For comparability, seizure frequency will be extrapolated per month (28 days);

0-12 months
Impact of cenobamate used as adjunctive therapy on epilepsy-related surgery
Tijdsspanne: 0-12 months

To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related surgery the following data will be collected:

  • the number of epilepsy-related surgery (how many patients initiated cenobamate while they were in waiting list or post-surgical intervention, i.e. surgical failure);
  • the number of hospitalizations due to surgery related to epilepsy (e.g. fractures due to falls);
  • the number of Intensive Care Unit (ICU) visits;
0-12 months
Impact of cenobamate used as adjunctive therapy on comorbidity-related healthcare resources utilization (HCRU)
Tijdsspanne: 0-12 months

To evaluate the impact of cenobamate used as adjunctive therapy on comorbidity-related HCRU, the following data will be collected:

  • Number and length of hospitalizations of all-cause inpatient visits,
  • Number of ER visits,
  • Number of outpatient visits. All-cause HCRU will be defined as HCRU due to any cause;
0-12 months
Impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions
Tijdsspanne: 0-12 months

To evaluate the impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions, the number of phone calls/virtual interventions will be collected.

0-12 months
Safety of cenobamate used as adjunctive therapy
Tijdsspanne: 0-12 months

To evaluate safety of cenobamate used as adjunctive therapy, the number, type and severity of, adverse events, adverse drug reactions will be collected. Moreover, changes in the number, type, dose of concomitant medications other than anti-seizure medications will be collected over the duration of the study.

0-12 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

19 december 2024

Primaire voltooiing (Werkelijk)

30 december 2025

Studie voltooiing (Werkelijk)

30 oktober 2026

Studieregistratiedata

Eerst ingediend

1 april 2025

Eerst ingediend dat voldeed aan de QC-criteria

9 april 2025

Eerst geplaatst (Werkelijk)

10 april 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 169(A)AV23432

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren